Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFortis Introduces Next Generation Biobanking Software Platform

Published: Monday, September 24, 2012
Last Updated: Sunday, September 23, 2012
Bookmark and Share
Helps organizations involved in biomarker-based clinical and translational research to safely and effectively conduct externalized, science-driven collaborative studies.

BioFortis Inc. has introduced its Next Generation Biobanking software platform for biomarker-based clinical research.

It will help pharmaceutical, government and academic research centers involved in biomarker-based clinical and translational studies to safely and effectively conduct externalized, science-driven collaborative studies.

As biomarker-based clinical research has become more commonplace, organizations have looked to biobanks to help drive these studies.

However, this approach poses significant challenges to conventional biobanks and their software.

The Next Generation Biobanking software platform is designed to overcome these challenges by harmonizing biospecimen data with clinical and molecular data in a collaborative environment that emphasizes scientific insights, while ensuring security and compliance.

At the core of the Next Generation Biobanking software solution is the Labmatrix® platform.

Labmatrix goes beyond the sample-centric workflows of conventional biobanking software by integrating patient, clinical, specimen, genetic and molecular assay data, to deliver holistic views of studies.

Multi-level user access control ensures that all collaborators can work effectively while maintaining relevant privacy and regulatory compliance objectives.

Driving scientific insights is one of the key benefits of Next Generation Biobanking software. Mining the wealth of data across studies, searching for the patterns within, and discovering knowledge requires tools that augment the user's own expertise.

To meet that need, the Next Generation Biobanking software platform provides Qiagram®, the award-winning visual ad hoc query tool.

Qiagram puts powerful query and knowledge discovery tools in the hands of the individual researcher.

Users "draw" their questions, interactively creating sophisticated queries, without the need to program or struggle with complicated query builders.

Answers are presented in configurable visualizations and dashboard widgets that can be shared to generate cross-study, cross-site and cross-group knowledge.

"Based on experiences with many pharmaceutical companies and academic centers, we believe that our Next Generation Biobanking software bridges the gap between conventional biobanking software and the needs of biomarker-based clinical research," commented BioFortis CEO, Jian Wang, PhD, "We consider it critical to empower researchers to perform these kinds of studies and deliver safer and effective clinical outcomes."

The BioFortis Next Generation Biobanking software platform will be demonstrated at Booth #226 at the 2012 Clinical Business Expo, September 19-20, Boston, MA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!